New hope for youngest leukemia patients: first trial of groundbreaking cell therapy
NCT ID NCT06609928
Summary
This study is testing a new, experimental cell therapy for children under 6 years old with a specific, hard-to-treat type of acute myeloid leukemia (AML) that has come back or not responded to other treatments. Doctors will collect a child's own immune cells, modify them in a lab to better target the cancer, and then infuse them back. The main goal of this early-phase trial is to find a safe dose and understand the side effects of this new treatment approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CHILDHOOD ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington/Seattle Children's Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.